The Dermatology Digest

MARCH 18, 2024

Food and Drug Administration (FDA) has accepted Journey Medical’s New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024. “We

Rosacea 74

Rosacea Medical Clinic Office 74

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). Zoryve foam was approved by the U.S.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

Natural Beauty Med Spa

APRIL 28, 2024

Laser skin resurfacing is a popular cosmetic treatment that has the potential to drastically improve the appearance of the skin. However, you might be reluctant to commit to it due to concerns about safety. Another factor that should be kept in mind is the professional that performs the treatment. Is it worth it?

Med Spa 52

Med Spa Scarring Safety Makeup 52

The Dermatology Digest

AUGUST 21, 2024

The trial did not show a statistically significant difference between the proportion of patients treated with TMB-001 responding to treatment after 12 weeks compared with patients treated with vehicle. After encouraging phase 2b results, we observed an unexpectedly high vehicle response in this trial.

Pharmaceutical 36

Pharmaceutical Clinic Office Safety 36

The Dermatology Digest

APRIL 18, 2024

Extra-strength 40U formulation of prabotulinumtoxinA-xvfs (Jeuveau, Evolus) performed well in a Phase 2 trial for the treatment of moderate to severe glabellar lines in adults. The safety profile was similar across all three arms and overall, 88.9% The safety profile was similar across all three arms and overall, 88.9%

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

FEBRUARY 22, 2024

for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

JANUARY 14, 2024

The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). of the total study population).

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

AUGUST 14, 2024

s VP-315 is showing promise in the treatment of basal cell carcinoma, according to Part 2 of its Phase 2 clinical trial. The key preliminary Part 2 results were: No dose-limiting toxicities or Treatment-Related Serious Adverse Events were reported. Verrica Pharmaceuticals Inc.’s It’s very, very exciting data.”

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

JANUARY 5, 2024

s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s VP-315 is a chemotherapeutic administered intratumorally.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

APRIL 17, 2024

Patient enrollment is now complete in Celldex’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). Patients then enter a follow-up phase for an additional 24 weeks.

Safety 36

Safety Injections Therapy Office 36

The Dermatology Digest

JANUARY 5, 2024

Food and Drug Administration (FDA) seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.

Rosacea 36

Rosacea Medical Office Safety 36

The Dermatology Digest

JULY 22, 2024

“This opportunity to improve patient access through wider usage of a life-changing biological treatment emphasizes STADA’s purpose of Caring for People’s Health as a Trusted Partner.” “We We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

The Dermatology Digest

JANUARY 24, 2024

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules in people with severe chronic hand eczema, according to results from the DELTA FORCE Trial, which is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.

Eczema 36

Eczema Safety Office Treatments 36

The Dermatology Digest

FEBRUARY 6, 2024

Food and Drug Administration (FDA) has issued a “no filing review issues identified” letter regarding Biofrontera’s sNDA (supplementary New Drug Application) which aims to increase the maximally approved dosage from one to three tubes of Ameluz per treatment.

Safety 28

Safety Office Therapy Ingredients 28

The Dermatology Digest

FEBRUARY 7, 2024

For the study, 255 participants were randomized into six treatment groups (placebo [n=43], 25 mg daily [n=43], 25 mg twice-daily [n=41], 50 mg daily [n=43], 100 mg daily [n=43], and 100 mg twice-daily [n=42]). Improvements were also consistent across Patient Reported Outcomes through Week 16.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

AUGUST 15, 2024

DermBiont’s SM-020 is performing well in an ongoing open label, multi-center Phase 2a study for the treatment of basal cell carcinoma (BCC), the Company reports. The safety of the drug product is being evaluated based on frequency of adverse events (AEs) and application site reactions (ASRs). and CEO of DermBiont, in a news release.

Clinic 36

Clinic Scarring Office Safety 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Making sure you are seeing a board-certified core cosmetic specialty physician (dermatologist, plastic surgeon, oculoplastic surgeon, or ENT facial plastic surgeon) in a real medical office is key.

Office 36

Office Surgery Safety Injections 36

The Dermatology Digest

JULY 23, 2024

Food and Drug Administration (FDA) approved XEOMIN (incobotulinumtoxinA) for the simultaneous treatment of forehead lines, frown lines, and crow’s feet. The total recommended XEOMIN dose for treatment is 20 units for glabellar frown lines, 20 units for horizontal forehead lines and 24 units for the crow’s feet for a total of 64 units.

Facials 36

Facials Partnerships Ingredients Injections 36

Fairlawn Aesthetic MD

JULY 19, 2023

It’s an innovative treatment in the field of aesthetic medicine that’s designed to help you look and feel your absolute best. The Cryo T-Shock procedure involves alternating cycles of cryo (cold) and thermo (heat) treatments applied directly to the skin. It’s a comfortable and safe treatment.

Treatments 36

Treatments Diet Consultations Consultation 36

Southeastern Esthetics Institute

AUGUST 23, 2016

Estheticians must obtain written permission and treatment plans through the physician overseeing the practice, with monitoring by the physician of all notations within patient charts, products and modalities used, and any other thought process made throughout the duration of treatment.

Esthetician 195

Esthetician Esthetics Document Office 195

The Dermatology Digest

JANUARY 11, 2024

Vtama cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, steroid-free, topical cream for both acute treatment and long-term management of AD. Vtama cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S.

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

New Age Spa Institute

APRIL 18, 2024

” Laser treatments for hair removal and skin rejuvenation are an often-connected part of the aesthetics industry, and there are some critical points to consider before pursuing a career in this field. This distinction is crucial for both practitioners and clients to understand, ensuring treatments are conducted safely and legally.

Legal 52

Legal Hair Removal Safety Esthetician 52

The Dermatology Digest

FEBRUARY 27, 2024

“The approval of SIMLANDI marks the first high-concentration, citrate-free biosimilar to Humira with IC status,” says Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

APRIL 22, 2024

Treatment was well-tolerated and no new safety signals were identified. Most patients on eblasakimab achieved EASI-90 and vIGA of 0 or 1 after just 16 weeks of treatment, with numbers unprecedented in other biologics AD studies. There were no reports of conjunctivitis or injection site reactions in the active or placebo arm.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

JANUARY 14, 2024

INTEGUMENT-1 and INTEGUMENT-2 (The INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis) were two identical Phase 3, parallel-group, double-blind, vehicle-controlled trials evaluating the safety and efficacy of roflumilast cream 0.15% in AD. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

DECEMBER 27, 2023

has received approval from the University of Miami to enroll patients for its first-in-human Phase 2a clinical trial of HT-001 topical gel for the treatment of skin toxicities associated with EGFR inhibitors. Researchers will compare HT-001 to the placebo in the second period to see if HT-001 provides a significant treatment effect.

Office 36

Office Safety Ingredients Treatments 36

US Dermatologt Partners

MARCH 27, 2024

While dermatologists and research scientists haven’t decided on one name for this cutting-edge treatment, red light therapy is quickly gaining popularity thanks to the skin-rejuvenating results researchers are noting in research studies. Reduces cancer treatment side effects. Initially, treatment will take place several times a week.

Therapy 41

Therapy Treatments Dermatology Safety 41

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. “It is important to have systemic treatments approved for CHE, both with and without atopic dermatitis. .

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

FEBRUARY 13, 2024

EscharEx is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds that is currently in the advanced stages of clinical development. The incidence of complete debridement during the daily treatment period (the first two weeks of the study) was 63.0% (95% CI=47.5-76.8) for Santyl.

Safety 36

Safety Marketing Office Clinic 36

The Dermatology Digest

FEBRUARY 8, 2024

Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

MARCH 9, 2024

For the 16-week phase 2 trial study, researchers evaluated the safety and efficacy of remibrutinib in 77 adults with moderate to severe HS for at least 12 months in two or more anatomical areas with 15 or fewer tunnels beneath the skin. The main reason for discontinuing treatment was patient choice. Fully 80.2% By contrast, 48.5%

Office 36

Office Safety Dermatology Medical 36

New Age Spa Institute

DECEMBER 19, 2023

Massage therapists may begin their journey in spas, holistic centers, doctor or chiropractor offices, rehabilitation centers, fitness facilities, sports medicine clinic, nursing homes, or hospitals. Can massage therapists perform body treatments ? Part time schedules complete in 10 months. Full time schedules complete in 5 months.

Private Practice 40

Private Practice Ethics Therapy Education 40

The Dermatology Digest

DECEMBER 15, 2023

The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. “This is a once-daily non-steroidal treatment that doesn’t have any duration on use,” Patrick Burnett, MD, PhD, chief medical officer at Arcutis, tells TDD. . in seborrheic dermatitis.

Dermatitis 36

Dermatitis Safety Clinic Medical 36

Art of Dermatology

SEPTEMBER 29, 2022

Dermatologists can also offer several cosmetic treatments to help you look and feel your best! At Art of Dermatology® at the Laser & Skin Surgery Center of New York, Dr. Krant offers the following cosmetic dermatology treatments. Dr. Krant’s in office peels are all superficial peels, which optimizes safety and comfort.

Chemical Peels 36

Chemical Peels Office Injections Wrinkles 36

The Dermatology Digest

AUGUST 30, 2023

Ted Lain, MD, MBA, board-certified dermatologist and Chief Medical Officer, Sanova Dermatology, Austin, Texas. In other words, how long it takes for patients to maintain no or mild wrinkles in the treatment area, he said. But many of his patients still prefer their regular treatment schedule, he said. J Drugs Dermatol.

Wrinkles 36

Wrinkles Office Safety Clinic 36